Stockscreener 앱 받기
16.93
0.29%
-0.05
전일 마감가:
$16.98
열려 있는:
$17
하루 거래량:
868.22K
Relative Volume:
1.65
시가총액:
$877.45M
수익:
$109.78M
순이익/손실:
$114.54M
주가수익비율:
7.6794
EPS:
2.2046
순현금흐름:
$268.74M
1주 성능:
+0.00%
1개월 성능:
+3.42%
6개월 성능:
-11.08%
1년 성능:
+47.73%
1일 변동 폭
$16.91
$17.02
1주일 범위
$16.91
$17.28
52주 변동 폭
$10.82
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
명칭
Theravance Biopharma Inc
전화
650-808-6000
주소
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
16.93 | 877.45M | 109.78M | 114.54M | 268.74M | 2.2046 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2026-03-04 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2025-12-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-12 | 개시 | B. Riley Securities | Buy |
| 2024-08-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | 개시 | BTIG Research | Buy |
| 2024-01-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-15 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-08-25 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 개시 | JP Morgan | Overweight |
| 2020-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 개시 | Cowen | Outperform |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-06 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 개시 | H.C. Wainwright | Buy |
| 2018-03-29 | 재개 | Piper Jaffray | Overweight |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-12-21 | 개시 | Needham | Buy |
| 2016-11-03 | 개시 | Piper Jaffray | Overweight |
| 2016-10-12 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 개시 | Guggenheim | Buy |
| 2016-06-20 | 재확인 | Leerink Partners | Outperform |
| 2016-05-12 | 개시 | Leerink Partners | Outperform |
| 2016-05-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
모두보기
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Liquidity Mapping Around (TBPH) Price Events - Stock Traders Daily
Theravance stock down 3% after Zymeworks announces buyout - MSN
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders - AOL.com
Theravance Biopharma Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co. - Moomoo
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI
TBPHTheravance Biopharma Inc Options - Finviz
If You Invested $1,000 in Theravance Bioph (TBPH) - Stock Titan
Arthur Cox advises on pharmaceutical sector acquisition - ICLG
Theravance Biopharma Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseEarnings Season Review - dars.gov.et
TBPH News | THERAVANCE BIOPHARMA INC (NASDAQ:TBPH) - ChartMill
Zymeworks to pay $17/share for Theravance Biopharma in $929M deal - MSN
Theravance Biopharma Insider Sold Shares Worth $5,791,555, According to a Recent SEC Filing - marketscreener.com
Theravance Biopharma Inc (TBPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Theravance Biopharma(TBPH.US) 10% Shareholder Sells US$5.79 Million in Common Stock - Moomoo
Funds tied to Eli Samaha trim Theravance Biopharma (TBPH) stake in open-market sales - Stock Titan
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
TBPH SEC FilingsTheravance Bioph 10-K, 10-Q, 8-K Forms - Stock Titan
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP
Zymeworks to Acquire Theravance Biopharma in $929 Million Transaction - Global Legal Chronicle
Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo
Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology
TBPH Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet
Zymeworks to Acquire Theravance Biopharma, Inc. - Indovizka.com
Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus
Zymeworks offers US$929-million for COPD drug maker Theravance - The Globe and Mail
Zymeworks to buy Theravance Biopharma in $929M deal – a look at what this deal means for TBPH shareholders - MSN
Zymeworks Buys Theravance To Execute On New Business Strategy - insights.citeline.com
Theravance Biopharma (TBPH) Downgraded to Hold Following $929M A - GuruFocus
Theravance downgraded at Jones on Zymeworks acquisition - MSN
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareh - GuruFocus
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? - Finviz
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH) - PR Newswire
TBPH Downgraded by Jones TradingRating Changed to Hold - GuruFocus
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Ther - GuruFocus
Theravance, after clinical setbacks, agrees to $929M buyout - BioPharma Dive
Zymeworks bolsters royalty stream with Theravance buy - BioWorld News
Zymeworks expands beyond cancer with $929 million Theravance acquisition - WTVB
Fair Price or Fast Exit? Scrutiny Mounts Over Theravance Biopharma Sale - BriefGlance
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal By Investing.com - Investing.com South Africa
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma - Pharmaceutical Executive
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal - Investing.com
Zymeworks to Acquire Theravance for $929 Million, But Discounted Price Triggers Shareholder Investigation - finance.biggo.com
Zymeworks to acquire Theravance Biopharma for $929M - grafa.com
Zymeworks makes bold move with $929m Theravance Biopharma buy - BioXconomy
Ademi LLP Investigates Whether Theravance Biopharma, Inc. Is Obtaining a Fair Price for Public Shareholders - Moomoo
BTIG Downgrades Theravance Biopharma to Neutral From Buy - Moomoo
Zymeworks Targets Long-Term Cash Generation Through Theravance AcquisitionTheravance Biopharma (NASDAQ - Benzinga
Theravance Biopharma Inc (TBPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Theravance Biopharma Inc 주식 (TBPH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Samaha Eli | 10% Owner |
Jul 01 '26 |
Sale |
17.00 |
37,799 |
642,628 |
9,174,453 |
| Samaha Eli | 10% Owner |
Jun 30 '26 |
Sale |
17.13 |
25,027 |
428,788 |
9,212,252 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Jun 15 '26 |
Sale |
16.39 |
13,314 |
218,167 |
232,457 |
2.64%
자본화:
|
볼륨(24시간):